Rheumatoid arthritis is a prototypical immune-mediated inflammatory disease that is characterized by increased cardiovascular morbidity and mortality, independent of the traditional risk factors for cardiovascular disease. Efforts to understand how the ‘chronic inflammatory state’ contributes to atherosclerotic disease, as well as to understand the molecular pathogenesis of atherosclerotic plaques, are leading to new targets for therapy.
Upon completion of this session, participants should be able to:
- review the data on the molecular pathogenesis of accelerated atherogenesis in rheumatoid arthritis and other immune-mediated inflammatory disorders
- identify the primary cellular and molecular pathways that are targeted by local and systemic inflammatory responses
- discuss the potential targets for therapy that may reduce the cardiovascular burden as well as disease activity in rheumatoid arthritis
|Moderators:||Joćo E. Fonseca, MD, PhD, Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt) and Radjesh J. Bisoendial, MD, PhD, Academic Medical Center/ University of Amsterdam|
To see other sessions for this day, use the date buttons to the left.